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Abstract 
Succinate-CoA ligase deficiency is responsible for encephalomyopathy with mitochondrial 
DNA depletion and mild methylmalonic aciduria. Mutations in SUCLA2, the gene encoding a 
β subunit of succinate-CoA ligase, have been reported in 17 patients until now. Mutations in 
SUCLG1, encoding the α subunit of the enzyme, have been described in two pedigrees only. 
We report two unrelated patients harboring three novel pathogenic mutations in SUCLG1. The 
first patient had a severe disease at birth. He was compound heterozygous for a missense 
mutation (p.Pro170Arg) and a c.97+3G>C mutation which leads to the complete skipping of 
exon 1 in a minigene expression system. The involvement of SUCLG1 was confirmed by 
western blot analysis, which showed absence of SUCLG1 protein in fibroblasts. The second 
patient has a milder phenotype, similar to that of patients with SUCLA2 mutations, and is still 
alive at 12 years of age. Western blot analysis showed some residual SUCLG1 protein in the 
patient’s fibroblasts. Our results suggest that SUCLG1 mutations that lead to complete 
absence of SUCLG1 protein are responsible for a very severe disorder with antenatal 
manifestations, whereas a SUCLA2-like phenotype is found in patients with residual SUCLG1 
protein. Furthermore, we show that in the absence of SUCLG1 protein, no SUCLA2 protein is 
found in fibroblasts by western blot analysis. This result is consistent with a degradation of 
SUCLA2 when its heterodimer partner, SUCLG1, is absent. 
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Introduction 
 
The mtDNA depletion syndromes (MDS) are a heterogeneous group of severe 
mitochondrial disorders of infancy and childhood, resulting from a decrease in mtDNA copy 
number in affected tissues 1-3. They are inherited as autosomal recessive traits. To date, eight 
genes have been involved in MDS which can be classified in two genetic categories, those 
that affect mtDNA replication and those that affect the mitochondrial nucleotide pool 4-11. 
Mutations in the SUCLA2 and SUCLG1 genes have been found in MDS associated with 
encephalomyopathic presentations, moderate methylmalonic aciduria 12 , 13 and succinate-CoA 
ligase (SUCL) deficiency. SUCL is an enzyme located in the mitochondrial matrix, composed 
of an α subunit encoded by SUCLG1 and a β subunit encoded by either SUCLA2 or SUCLG2, 
resulting in an ATP-specific SUCL (A-SUCL) and a GTP-specific SUCL (G-SUCL) 
respectively. A-SUCL and G-SUCL are supposed to catalyse the reversible conversion of 
succinyl-CoA and ADP or GDP to succinate and ATP or GTP in the Krebs cycle 14. Several 
studies have demonstrated that SUCL forms a complex with nucleoside diphosphate kinase 
(NDPK), which is involved in the salvage of deoxyribonucleotides 15. An absence of 
interaction with SUCL could lead to a decreased activity of NDPK and explain the mtDNA 
depletion observed in SUCL deficiency 16. 
To date, mutations in SUCLA2 have been identified in 12 families, including 8 families of the 
Faroe islands who have a common ancestor 12 , 17 , 18. Most patients were normal at birth but 
later developed a Leigh-like disorder with dystonia and hearing impairment 19. Only four 
patients have been reported with SUCLG1 mutations. In one pedigree, the three patients 
carried a homozygous 2 bp deletion 13. They had a severe lactic acidosis at birth and died 
within 2-4 days, suggesting that MDS linked to SUCLG1 mutations are more severe than 
those caused by SUCLA2 mutations. Recently though, an additional patient with a 
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homozygous missense mutation in SUCLG1 who presented with a milder phenotype, similar 
to that of patients with SUCLA2 mutations, was reported 20.  
In this study, we describe two unrelated patients harboring novel pathogenic mutations 
in SUCLG1 and suggest that the severity of the phenotype is modulated by the presence of a 
residual amount of SUCLG1 protein.  
Patients and methods 
Patients 
Patient 1 was the second child of unrelated healthy parents. Pregnancy and birth were 
unremarkable. At age 1 day, he was admitted to intensive care unit with severe hypotonia, 
respiratory failure and hypoglycemia. Laboratory investigations revealed a lactic acidosis 
(blood pH 6.76, normal 7.4; HCO3- 4.8mmol/l, normal>18 mmol/l; plasma lactate 
concentration of up to 11.31mmol/l, normal<2.20mmol/l) and a high lactate/pyruvate ratio 
(33, normal<18). Lactate concentration in cerebrospinal fluid was elevated (22.68mmol/l, 
normal<3.10mmol/l). Measurement of acylcarnitine esters in plasma revealed increased levels 
of C3-carnitine (7.5µmol/l, normal<1µmol/l) and C4-dicarboxylic acylcarnitine, which reflect 
an elevated excretion of methylmalonic acid. The brain magnetic resonance (MR) imaging 
showed symmetric T2-hyperintense lesions of the basal ganglia and MR spectroscopy in 
single-voxel revealed a significant elevated lactate doublet peak within abnormal white matter 
(Fig.1). At age 7 months, psychomotor development was severely delayed with no head 
control, severe axial hypotonia and poor spontaneous movements. He presented with recurrent 
episodes of acidosis and respiratory failure. He died at age one year.  
Patient 2 was the second son of unrelated healthy parents. Pregnancy and birth were 
unremarkable. At 3 months of age, he presented with severe hypotonia, feeding difficulties 
and failure to thrive. Metabolic findings were similar to those of the first patient (lactic 
acidosis and moderate excretion of methylmalonic acid). At 14 months of age, he presented 
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with severe psychomotor retardation with lack of head control and sitting posture. Brain 
magnetic resonance imaging (MRI) is shown in figure 1. At present, he is 12 years old. 
Clinical examination shows an extremely severe axial hypotonia with no active movements 
and very atrophic muscles. The patient is tube-fed through a percutaneous endoscopic 
gastrostomy and he needs permanent respiratory support by tracheotomy.  
 OXPHOS spectrophotometric measurements 
Spectrophotometric studies of OXPHOS complexes and citrate synthase were performed on 
fibroblasts and muscle crude homogenates, as previously described 21, 22.  
Western blotting 
50 µg of total protein extracts, obtained as previously described 6, were separated on an 
acrylamide gel by SDS-PAGE and transferred to a PVDF membrane (Millipore, Saint-
Quentin, France). Different primary antibodies have been used. A cocktail of anti-human total 
OXPHOS complex antibodies (Mitosciences, Eugene, USA) was used at 1/1000. For 
detection of the SUCLG1 protein, a rabbit polyclonal antibody was used at 1/1000 13. For 
SUCLA2 detection, a rabbit polyclonal antibody against amino acids 53-348 was used at 
1/200 (Santa Cruz Biotechonology). Beta-tubulin detection was performed with a mouse 
monoclonal antibody at 1/10000 (Sigma-Aldrich, St Louis, USA). Anti-rabbit HRP-
conjugated secondary antibody was used at 1/20000 and signals were detected using an 
Enhanced Chemiluminescence system (ECL Plus, Amersham, Piscataway, USA). 
Mitochondrial DNA analysis 
Blood and tissue samples were obtained after parents had given informed consent. 
Mitochondrial DNA quantification in muscle was performed by real-time quantitative PCR 
adapted from the method described by Sarzi et al. 23. Primers and conditions are available on 
request. 
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Sequencing of SUCLG1, SUCLA2, SUCLG2 and NME4 
The coding exons of SUCLG1 (NM_003849.2), SUCLA2 (NM_003850.2), SUCLG2 
(NM_003848.2) and NME4 (NM_005009.2) genes were amplified with intronic primers by 
using standard conditions (primers and PCR conditions are available on request). PCR 
products were purified with ExoSAP-IT enzyme (USB, Cleveland, Ohio, USA), processed 
with an ABI PRISM® dRhodamine Terminator Cycle Sequencing Ready Reaction kit 
(Applied Biosystems, Foster City, CA, USA) and analyzed on an ABI 3130 automated 
sequencer (Applied Biosystems).  
PCR-RFLP analysis.  
We searched for the presence of the c.509C>G mutation in 360 control chromosomes by 
PCR-RFLP analysis. This mutation abolishes an ApaI restriction site in exon 4 which was 
amplified with a forward primer in intron 3 : 5’-TGTCCTTTTCTTACCCCAAGA-3’ and a 
reverse primer in intron 4 : 5’-GAGTTTTGAGGGTTTAAGGCA-3’. After ApaI digestion, 2 
fragments of 292 and 280 bp are found in wild-type PCR controls. The 572 bp PCR fragment 
is not digested when the c.509C>G mutation is present.  
In silico analysis 
The model (residues 41 to 346) was obtained by comparative protein modeling methods and 
energy minimization using the Swiss-Model program. The 2.96 Å coordinate set for the pig 
enzyme in complex with GDP (pdb code 2fpg) was used as a template for modeling the 
human enzyme. Swiss-pdb Viewer 3.7 (http://www.expasy.org/spdbv) was used to analyze 
and visualize the structures. 
RT-PCR analysis 
Total RNA were extracted by using the Trizol reagent (Invitrogen, Carlsbad, CA) according 
to the manufacturer’s instructions. cDNA synthesis and PCR amplifications were performed 
using the SuperScript One-Step kit, RT-PCR with Platinum Taq (Invitrogen). Reverse 
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transcription consisted of one cycle at 55°C for 30 min and 94°C for 2min and was followed 
by PCR amplification (primers and PCR conditions are available on request). 
Ex vivo splicing assay 
An overlap extension PCR strategy 24 was used, due to the large size of SUCLG1 intron 1 (9.4 
kb), to construct a chimeric minigene assembling SUCLG1 exon 1 with its upstream (498 bp) 
and downstream (173 bp) intronic sequences (fragment 1) and exon 2 with its flanking 
intronic sequences (406 bp of intron 1 and 146 bp of intron 2) (fragment 2). The PCRs were 
performed from the genomic DNA of patient 1 using the Hot Start High Fidelity Phusion 
polymerase (Finnzymes). Sequences of primers are available upon request. The final full-
length product (1617 bp) was inserted between the XhoI/NheI restriction sites of the 
pcDNA3.1(+) mammalian expression vector (Invitrogen) using the T4 DNA ligase 
(Invitrogen) and validated by direct sequencing. Transient transfections in HeLa cells were 
carried out in 6-well plates using 6 μl of FuGENE6 (Roche) and 1 μg of wild-type or mutated 
minigene constructs according to the manufacturer’s instructions. Experiments were carried 
out in triplicate and in at least two independent transfections. Cells were harvested 48 h post 
transfection. Total cytoplasmic RNA was extracted using the Nucleospin RNAII Kit 
(Macherey-Nagel). First-strand cDNA synthesis was performed from 1 μg of total RNA, with 
random hexamers as primers (Invitrogen) and Superscript II (Invitrogen). One tenth of the 
synthesized cDNA was used as a template for the subsequent PCR with the T7 forward vector 
specific primer and a gene-specific reverse primer (5’-CTGTTTGCCAGTGAAACCCTGG-
3’). Amplification was performed using the Hot Start High Fidelity Phusion polymerase 
(Finnzymes) for 35 cycles, consisting of 10 sec at 98°C, 20 sec at 53°C and 50 sec at 72°C. 
The products were resolved on 1.5% agarose gel. All PCR products were confirmed by DNA 
sequencing.  
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Results 
Patient 1  
Histological analysis of the muscle tissue showed intracellular lipid accumulation with 
numerous cox-negative and a few ragged-red fibers (not shown). Enzymatic 
spectrophotometric measurements of the individual respiratory chain complexes in muscle 
revealed a decrease of complex I, II, IV and V activity (Table 1A). Additionally, all activity 
ratios compared to complex IV, which best reflect the balanced respiratory enzyme activity 25, 
were severely abnormal in muscle. In fibroblasts, the specific activities of complex II, III, and 
IV were also decreased with an imbalance in the ratios between the complexes (Table 1B).  
Table 1A 
MUSCLE BIOPSY 
OXPHOS complexes I II III IV V CS 
Control values (nmol/min/mg of proteins) 10-32 20-65 94-236 89-347 32-89 82-234 
Patient 6.9 15.2 157.9 21.3 24.2 107.2 
Ratios IV / I IV / II IV / III IV / V IV / CS  
Control values 5.54-21.20 3.20-7.90 1-2 2.59-5.40 1.01-2.16  
Patient 3.08 1.40 0.13 0.88 0.19  
 
 
Table 1B 
FIBROBLASTS 
OXPHOS complexes I II III IV V CS 
Control values (nmol/min/mg of proteins) 9.0-27.1 8.6-20.2 57.4-176.2 109.9-252.7 22.0-46.2 74.7-161.1 
Patient 11.6 7.5 47.9 78.1 37.6 116.6 
Ratios IV / I IV / II IV / III IV / V IV / CS  
Control values 5.02-21.78 6.38-24.65 0.98-3.76 2.83-7.98 1.04-2.71  
Patient 6.73 10.41 1.63 2.07 0.67  
 
In agreement with the enzyme measurements, western blot analysis demonstrated a marked 
reduction in the amount of specific proteins of complexes I, II, III and IV in patient’s 
fibroblasts compared to control (Fig. 2A). Muscle was not available for western blotting 
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analysis. The relative mtDNA copy number showed a decreased amount of mtDNA in muscle 
(11% of age-matched controls). 
The clinical presentation including encephalomyopathy with mtDNA depletion and mild 
methylmalonic aciduria led us to perform mutation screening of genes involved in succinate-
CoA ligase. No mutation was found in SUCLA2. Mutation analysis of the SUCLG1 gene 
showed that the patient was compound heterozygous for 2 novel mutations: c.509C>G 
(p.Pro170Arg) and c.97+3G>C (Fig. 2B). The involvement of SUCLG1 was confirmed by 
western blotting analysis which showed a total absence of SUCLG1 protein in patient’s 
fibroblasts (Fig. 2C).  
The c.509C>G mutation was inherited from the mother, and the healthy older sister was also 
heterozygous for the mutation. The missense mutation changes a highly conserved neutral 
proline into a polar charged basic arginine and was not found in 360 healthy French control 
chromosomes (Fig. 2D). The p.Pro170Arg mutation maps within the CoA-ligase domain and 
we carried out prediction studies of putative impact on SUCL-G structure and function. The 
high degree of identity (96%) between the pig GTP-specific succinyl CoA synthetase and 
SUCL-G α-subunits prompted us to predict the three-dimensional structure of the human 
enzyme. The missense mutation p.Pro170Arg is localized close to the catalytic histidine 
residue and the CoA-binding domain. The putative creation of an ionic bound with one of the 
neighbouring acidic residues could alter the flexibility of the loop connecting the two domains 
of the α-subunit (Fig. 3).  
The second mutation c.97+3G>C, inherited from the father changes the highly conserved G 
nucleotide at position +3 of the donor splice site (5’ss) in intron 1. This base substitution was 
predicted to drastically decrease the intrinsic strength of this 5’ss by using three different 
splice-site prediction algorithms (MaxEntScan available at 
http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html, Splice-site Neural 
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Network algorithm (SSPNN: NNSPLICE 0.9 version) available at http://www.fruitfly.org and 
SpliceSiteFrame available at http://ast.bioinfo.tau.ac.il/SpliceSiteFrame.htm). We first 
attempted to characterize the splicing outcome of this sequence variation by RT-PCR analysis 
from patient’s fibroblasts, with a forward primer in exon 1 and a reverse primer in the last 
exon of SUCLG1 (exon 9). No aberrantly spliced mRNA could be identified and sequence 
analysis of the RT-PCR reaction detected only one allele with the 509 C to G mutation. Hence 
we designed a splicing reporter minigene containing exon 1 and exon 2 of SUCLG1 with part 
of their flanking intronic sequences, containing a strong cryptic 5’ss predicted by the Human 
Splicing Finder (HSF) tool (http://www.umd.be/HSF/) which was located 314 bp upstream 
exon 1, to perform an ex vivo splicing assay (Fig. 4A). After transfection into HeLa cells, the 
effects on splicing were evaluated by RT-PCR analysis and systematic sequencing. No 
transcript retaining exon 1 could be detected in presence of the mutation. Indeed, the mutant 
minigene disclosed only a short fragment resulting from the complete skipping of exon 1 by 
the occurrence of a splicing event between the upstream cryptic 5’ss together with the 
acceptor splice site (3’ss) in intron 1 (Fig. 4A). In the wild-type context, two transcript species 
were detected. In both transcripts, the cryptic 5’ss was used either in combination with the 
3’ss in intron 1 (transcript missing exon 1) as observed in the mutant or with a new cryptic 
exonic 3’ss (MaxEntScan score, 4.97) located 5 base pairs downstream of the established 5’ 
border of exon 1 (transcript including exon 1) which preserves the translation initiation site 
(Fig. 4A). To further investigate in vivo the functionality of the two newly identified 5’ss and 
3’ss, we performed a new RT-PCR analysis from both patient and control fibroblasts with a 
forward primer located upstream the cryptic 5’ss sequence. As observed in the wild-type 
construct, we confirmed the presence of two SUCLG1 mRNA isoforms in control fibroblasts 
resulting from alternative splicing of exon 1. Both isoforms contain an exonic sequence, 
upstream of exon 1, bound either to exon 1 (use of the cryptic exonic 3’ss) or to exon 2 (Fig. 
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4B). The same transcripts were found in patient’s fibroblasts because of the presence of the 
wild-type allele. Hence we have evidenced the presence of a so-far unreported exonic 
sequence upstream of SUCLG1 exon 1, which is likely untranslated when bound to exon 1. 
We have found a cDNA sequence corresponding to the second isoform lacking exon 1 in 
databases (BU600891; www.genome.ucsc.edu; www.ensembl.org). Nevertheless, the role of 
the putative corresponding gene product, which lacks the initiation AUG codon and the 
mitochondrial targeting sequence, has to be determined.  
Patient 2  
At 2 years of age, analysis of muscle showed numerous cox-negative fibers and lipid 
accumulation (not shown). On electron microscopy, abnormal enlarged mitochondria 
contained lipid droplets (Fig. 5A). Enzymatic spectrophotometric measurements showed 
markedly reduced activities for complexes I and IV (not shown) and we found a mtDNA 
depletion (18% of age-matched controls). No mutation was identified by sequencing the 
SUCLA2 gene. Mutation analysis of SUCLG1 showed that the patient was heterozygous for a 
c.448C>T (p.Gln150X) mutation (Fig. 5B), which was inherited from his healthy mother. We 
failed to identify a second mutation by SUCLG1 sequencing. Furthermore, we did not detect 
any sequence variation by sequencing the complete cDNA from fibroblasts. Immunoblot 
analysis of fibroblasts showed a decreased amount of SUCLG1 protein in patient compared 
with controls (Fig. 5C).  
A-SUCL is a heterodimer composed of SUCLG1 and SUCLA2. We looked at the expression 
of SUCLA2 protein in our patients harboring SUCLG1 deficiencies. Western blotting in 
fibroblasts of patient 1, who harbors a complete absence of SUCLG1 protein, showed no 
expression of the SUCLA2 gene product (Fig. 5D). On the contrary, we only found a 
decreased amount of SUCLA2 when a residual amount of SUCLG1 protein is present 
(patient 2). These results are consistent with a destabilization of SUCLA2 in the absence of its 
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heterodimer partner, SUCLG1. 
Discussion 
The first patients described with SUCLG1 mutations had a very severe phenotype at 
birth with death during the first days of life 13. Patients with SUCLA2 mutations had a milder 
phenotype. They were generally normal at birth and later developed psychomotor retardation, 
severe muscle hypotonia, hyperkinetic movement disorders and sensorineural deafness 12 18 17. 
Recently, Ostergaard et al. described a patient with SUCLG1 mutations, presenting with a 
phenotype similar to that of patients with SUCLA2 mutations. Our patient 1 had a complete 
absence of SUCLG1 protein in fibroblasts. He presented with severe hypotonia and lactic 
acidosis at birth. He developed psychomotor development with recurrent episodes of acidosis 
leading to death at one year of age. Our patient 2 had a residual amount of SUCLG1 in 
fibroblasts. The first symptoms appeared at 3 months of age and he is still alive at 12 years of 
age. Similarly, Ostergaard et al. described a severe disease in patients showing a complete 
absence of SUCLG1 while the patient who expressed small amount of SUCLG1 protein 
presented with a “SUCLA2-like” phenotype 13, 20. All together, these results suggest that the 
severity of the phenotype is modulated by a residual amount of SUCLG1 enzyme. 
Furthermore, we show that in fibroblasts a complete absence of SUCLG1 likely leads to 
degradation of SUCLA2, its heterodimer partner. It is reasonable to assume that an extremely 
severe phenotype with antenatal manifestations is observed when the absence of SUCLG1 
leads to a complete abolition of both G-SUCL and A-SUCL activities. In patients with 
SUCLA2 mutations or SUCLG1 mutations that do not fully abolish SUCLG1 expression, 
some residual SUCL activity is present and the interaction with NDPK could be conserved 
thus  NDPK activity. 
Brain imaging in most patients with SUCLA2 mutations showed basal ganglia involvement 
closely resembling Leigh syndrome 12, 18 17. Brain MRI data were available for only one 
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patient with SUCLG1 mutations showing findings similar to that of patients with SUCLA2 
mutations 20. Our SUCLG1 patients also showed basal ganglia abnormalities. In addition, we 
found in both patients bilateral and symmetrical white matter involvement, which has not 
been reported previously. Albeit, neuroimaging of only a few patients has been reported, it 
does not seem to be associated with mutations in a specific gene and both SUCLA2 and 
SUCLG1 genes have to be tested in patients with encephalomyopathic presentations 
associated with mild methylmalonic aciduria.  
We have strong arguments for the pathogenicity of the three novel mutations that we 
detected. In patient 1, p.Pro170Arg affects highly conserved residue during evolution and was 
not found in 180 controls. Its location within the CoA-ligase domain and the prediction 
studies of its putative impact on SUCL-G structure and function are in favor of a deleterious 
effect. Indeed, this mutation may induce a local conformational change, altering the 
flexibility, proper interface interactions and ligand binding. In a more dramatical way, the 
p.Pro170Arg mutation may completely disrupt the local tertiary structure of the protein 
leading to a wrong folding which would explain why the protein is unable to form a complex 
with the β subunit. The second heterozygous mutation in patient 1, c.97+3G>C, was predicted 
to affect the 5’ss in intron 1. By using an ex vivo splicing assay, we demonstrated that this 
variant results in the skipping of exon 1 in all transcripts leading to the loss of the AUG 
initiation codon and the mitochondrial targeting sequence located in the first 40 amino acids 
of the SUCLG1 protein. Both ex vivo and in vivo assays on control fibroblasts showed the 
inclusion of an exonic sequence upstream of the exon 1 in the SUCLG1 transcripts, the role of 
which remains to be determined. Combined with the results of the immunoblot analysis 
showing the complete absence of SUCLG1 protein in the patient’s fibroblasts, we 
demonstrate that the identified mutations result in the absence of a functional protein.  
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The heterozygous nonsense mutation p.Gln150X in patient 2 is expected to lead to the 
synthesis of a truncated protein which lacks the CoA-ligase domain. Unfortunately, we failed 
to identify a second mutation in SUCLG1, but we did not search for large deletions or deep 
intronic mutations. Sequencing of SUCLA2, SUCLG2 and NME4 (coding for the 
mitochondrial NDPK) revealed no mutation. Taken together, these findings and the severe 
decrease of SUCLG1 protein on immunoblot analysis are in favour of the involvement of 
SUCLG1 in the disease.  
In conclusion, we confirm the role of SUCLG1 in encephalomyopathy with mtDNA 
depletion and mild methylmalonic aciduria. Overlap between the clinical presentations linked 
to SUCLG1 or SUCLA2 mutations should lead to screening of both genes in these phenotypes. 
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Titles and legends to figures 
Table 1. Respiratory chain enzyme activities in muscle biopsy (A) and fibroblasts (B) of 
patient 1. Activities were measured spectrophotometrically. Results are expressed i) as 
absolute values for controls or patient (in nanomol of substrate per minute per milligram of 
protein) and ii) as activity ratios compared to complex IV. The abnormal values are in bold. 
Figure 1. Brain MR images of patient 1 (A-D) and patient 2 (E-H). A. Axial T1-weighted 
image revealing slight symmetrical hyperintensities in the posterior lenticular nuclei (arrow) 
and the limb of internal capsula associated with T1 hypointensities in the frontal 
periventricular white matter. B. Axial diffusion-weighted image showing a decrease of 
Apparent Diffusion Coefficient in the posterior putamen. C-D. Single-voxel MR spectroscopy 
of the abnormal right parietal white matter revealing a prominent lactate peak which is clearly 
visible as an inverted doublet (arrow). E-F. Axial T2-weighted and FLAIR (FLuid-Attenuated 
Inversion Recovery) images showing brain atrophy with enlarged sylvian fissures, bilateral 
and symmetrical atrophy of putamen, caudate nuclei and globi pallidi with high signals on T2-
weighted and low signals on FLAIR. G. Axial FLAIR image showing symmetrical 
hyperintensities in middle cerebellar peduncles and dentate nuclei. H. Axial T1-weighted 
image showing symmetrical hypointensities of ventral mesencephalon (corpora 
quadrigemina). 
Figure 2. Identification of novel SUCLG1 mutations leading to G-SUCL defect in 
patient 1. A. Western blot analysis of patient’s fibroblasts. Equal amounts of proteins from 
patient 1 (P) and a control subject (C) were subjected to SDS-PAGE and blotted onto a PVDF 
17 
membrane prior to incubation with a cocktail of anti human total OXPHOS complexes 
monoclonal antibodies. B. Sequence analysis of SUCLG1 showing the c.509C>G (upper 
panel) and the c.97+3G>C (lower panel) mutations. C. Western blot analysis of patient’s 
fibroblasts. Equal amounts of proteins from controls (C1 and C2) and patient 1 (P) were 
subjected to SDS-PAGE and blotted onto a PVDF membrane prior to incubation with 
antibodies against SUCLG1 (upper panel) and β-tubulin (lower panel). D. Alignments of 12 
vertebrate amino acid sequences including the proline in position 170 (surrounded by a red 
rectangle). 
Figure 3. Modelled structure of the human SUCLG1 protein. A. The modelled α-subunit 
of SUCL-G is represented in yellow and green and superimposed with the grey dimeric 
template (dark grey for the α-subunit and light grey for the β-subunit). Pro170 located in the 
α-subunit of SUCL-G is shown in red. The pig GTP-specific succinyl-CoA synthetase was 
co-crystalized with GDP (in magenta), potassium ion (in light blue) and a phosphate ion (in 
orange). The α-subunit includes a doubly wound parallel β-sheet or nucleotide binding motif 
(“Rossmann fold”). Interestingly, the missense mutation p.Pro170Arg is localized on a loop 
linking these two domains and may create an ionic bound with Glu145 (in brown) or Asp229 
(in dark blue) close to the mutated residue. B. The modelled α-subunit of SUCL-G is 
represented in yellow and green as in figure 3A, but in another orientation. The E. coli 
succinyl-CoA synthetase (pdb code: 1scu) has been co-crystallized with the coenzyme A 
(CoA). The α-subunit of E. coli enzyme is depicted in grey, and the CoA bound in the N-ter 
of the α-subunit is shown in blue. The E. coli catalytic phosphorylated histidine residue is 
shown in black and orange. 
Figure 4A. Ex vivo analysis of the c.97+3G>C mutation. The genomic DNA segment tested 
is shown schematically above the panel. Black boxes (marked V) represent exons of the 
splicing reporter minigene. E1, SUCLG1 exon 1. E2, SUCLG1 exon 2. I1, SUCLG1 intron 1. 
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ss, splice site. Intron sequence is shown in lower case, exon sequence in upper case. The 
triangle represents the 8841bp deletion in intron 1 made by PCR overlap. Splicing patterns, 
determined by sequencing each product, are shown schematically alongside the right-hand 
margin of the gel. M, molecular weight marker. wt, wild-type. m, mutant. (-), negative control 
without reverse transcriptase. In the mutant, there is a complete abolition of the 5’ss of exon 1 
in favor of a cryptic 5’ss, marked gt, upstream of exon 1 and leading to exon 1 skipping. In 
the wild-type construct, the same cryptic donor site is used either with the 3’ss in intron 1 or 
with a newly identified cryptic 3’ss at the beginning of exon 1. B. In vivo analysis of the 
c.97+3G>C mutation. The position of the PCR primers used after reverse transcriptase step 
is indicated in left panel (small arrows). All RT-PCR products shown have been sequenced 
and their sizes are marked alongside the right-margin of the gels. P, patient. C1, C2 control 
subjects. bp, base pair. Upper panel, nested PCR performed with a forward primer upstream 
of the cryptic 5’ss and a reverse primer in exon 1. Middle panel, nested PCR performed with a 
forward primer in exon 1 and a reverse primer in exon 2. Lower panel, PCR performed with a 
forward primer upstream of the cryptic 5’ss and a reverse primer in exon 2. 
Figure 5A-C. SUCLG1 defect in patient 2. A. Electron micrographs showing abnormal 
enlarged mitochondria and lipid droplets in muscle fibers. Original magnification, x12000. B. 
Sequence analysis of SUCLG1 showing the c.448C>T mutation on the non-coding strand. C. 
Western blot analysis of patient’s fibroblasts. Equal amounts of proteins from controls (C1 
and C2) and patient 1 (P) were subjected to SDS-PAGE and blotted onto a PVDF membrane 
prior to incubation with antibodies against SUCLG1 (upper panel) and β-tubulin (lower 
panel). D. Western blot of SUCLA2 in patients 1 and 2. Equal amounts of fibroblast 
proteins from patients (P1 and P2) and controls (C1 and C2) were subjected to SDS-PAGE 
and blotted onto a PVDF membrane prior to incubation with antibodies against SUCLA2 
(upper panel) and β-tubulin (lower panel). 
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